October 1, 2007 - Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the initiation of a Phase I clinical trial to assess the safety and tolerability of an oral single dose of the R(+) isomer of zileuton in healthy subjects. R(+) zileuton combined in equal proportion with its mirror image isomer, S(-) zileuton, comprise racemic zileuton, which is the pharmaceutical ingredient in ZYFLO® (zileuton tablets) and ZYFLO CR(TM) (zileuton) extended-release tablets...In addition to asthma, the successful development of the R(+) isomer may also allow for possible development opportunities in other diseases - such as Chronic Obstructive Pulmonary Disease.. Critical Therapeutics' Press Release -
Oct 2, 2007
Critical Therapeutics, Phase I Clinical Trial of the R(+) Isomer of Zileuton
October 1, 2007 - Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the initiation of a Phase I clinical trial to assess the safety and tolerability of an oral single dose of the R(+) isomer of zileuton in healthy subjects. R(+) zileuton combined in equal proportion with its mirror image isomer, S(-) zileuton, comprise racemic zileuton, which is the pharmaceutical ingredient in ZYFLO® (zileuton tablets) and ZYFLO CR(TM) (zileuton) extended-release tablets...In addition to asthma, the successful development of the R(+) isomer may also allow for possible development opportunities in other diseases - such as Chronic Obstructive Pulmonary Disease.. Critical Therapeutics' Press Release -
